Globus Medical, Inc. Class A Stock News

This medical products stock breaks out of a cup-with-handle base and is in a buy zone. The company makes technology used for spine surgery.

Globus Medical's spine business is a big earnings driver, propelling its stock closer to a buy point.

Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic growth and a significant hike in full-year adjusted earnings guidance to $3.80 per share. Despite a 35% share price surge, shares trades at a reasonable 21x earnings, supported by a strong balance s...

Shares of the medical technology company are headed for their largest same-day percentage increase on record.

The image featured for this article is © Thinkstock

Globus Medical, Inc. ( GMED ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Brian Kearns - Senior Vice President of Business Development & Investor Relations Keith Pfeil - CEO, President & Director Kyle Kline - Senior VP & CFO Conference Call Participants Richard Newitter - Truist Securities, Inc., Research Division Vikramjeet Chopra - Wells Fargo Securities, LLC, Rese...

AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025.

Here's why we believe Globus Medical (GMED) stock merits attention as a value stock. It's currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that falls below the average over the past 3 years.